Physician profile
Subin Jain
NPI 1437131166
$7,041.60
in general payments reported to CMS, 2019-2025
47 companies · $1,133 in 2025
The $1,133 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,910 · 2020: $972 · 2021: $540 · 2022: $609 · 2023: $858 · 2024: $1,019 · 2025: $1,133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,879 · Education: $131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,878.81 |
| Education | $131.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $861.63 | 2019-2024 | Ofev |
| Pfizer INC. | $801.45 | 2019-2025 | |
| Glaxosmithkline, LLC. | $608.02 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Insmed, INC. | $579.81 | 2019-2025 | Arikayce, Brinsupri |
| Harmony Biosciences LLC | $574.60 | 2020-2025 | Wakix |
| Regeneron Healthcare Solutions, INC. | $371.70 | 2019-2025 | Dupixent, Libtayo |
| Jazz Pharmaceuticals INC. | $345.90 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $326.36 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Mylan Specialty L.P. | $215.90 | 2019-2024 | Yupelri |
| Actelion Pharmaceuticals US, INC. | $180.99 | 2020-2025 | Uptravi, Opsumit |
| Axsome Therapeutics, INC. | $142.03 | 2023-2025 | Sunosi |
| Grifols USA, LLC | $140.20 | 2020-2024 | Prolastin-C Liquid |
| Amgen INC. | $136.45 | 2022-2025 | Tezspire, Tavneos |
| Becton, Dickinson and Company | $131.45 | 2024 | Hemosphere |
| Pulmonx Corporation | $126.03 | 2019 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Subin Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.